Magnolol as a Radiotherapy Enhancer in Oral Squamous Cell Carcinoma: Targeting the EGFR/NF-κB Pathway and Immune Modulation.

ABSTRACT: Oral cancer, particularly oral squamous cell carcinoma (OSCC), often exhibits resistance to standard treatments like surgery, chemotherapy, and radiation therapy (RT). Magnolol, a bioactive compound from the bark of Magnolia officinalis, is recognised for its anti-inflammatory, antioxidant, antimicrobial, and antitumor properties. This study aims to explore magnolol's potential to enhance the therapeutic efficacy of RT in oral cancer models. Using MOC1-bearing animals, we evaluated the combined effect of magnolol and RT. The results showed that magnolol significantly suppressed tumour growth, delayed progression, and reduced tumour weight compared to control groups. Immune profiling revealed that magnolol plus RT promoted positive immune regulation by increasing M1 macrophages, dendritic c

SUBMITTER: Liu YC 

PROVIDER: S-EPMC12364617 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature